Last reviewed · How we verify
NCT05421793
Prebiotic and Anti-inflammatory Effects of a Pectin Polysaccharide
NA trial testing Fermented product of carrot derived rhamnogalacturonan I in Healthy in 17 participants. Completed in 30 August 2023.
30 July 2023
Quick facts
| Lead sponsor | Örebro University, Sweden |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 17 |
| Start date | 6 June 2022 |
| Primary completion | 30 July 2023 |
| Estimated completion | 30 August 2023 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Fermented product of carrot derived rhamnogalacturonan I
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Örebro University, Sweden
Who can join
Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to determine, quantify and understand the potential prebiotic and anti-inflammatory effects of the pecticpolysaccharide rhamnogalacturonan I (RG-I). The effects of these dietary fibre fractions on barrier function will also be investigated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05421793
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Örebro University, Sweden trials
Trials by the same sponsor.
- NCT07521709 — Evaluation of an Online ACT and Compassion-based Intervention for Disorders of Gut-Brain Interaction · NA · not yet recruiting
- NCT07350239 — Clinical, Microbial and Tissue-based Characterization of Patients Treated for Severe Temporomandibular Joint Pathology · not yet recruiting
- NCT07527793 — Monitoring Changes in Blood Circulating Metabolites Using Minimally Invasive Techniques · NA · recruiting
- NCT07175402 — Feasibility and Acceptability of an Online ACT Intervention for Disorders of Gut-Brain Interaction - Beta Trial · NA · completed
- NCT06887751 — Feasibility and Acceptability of an Online ACT Intervention for Disorders of Gut-Brain Interaction · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05421793 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Örebro University, Sweden
- Last refreshed: 21 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05421793.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing